Results 241 to 250 of about 396,292 (302)
Some of the next articles are maybe not open access.
European Journal of Preventive Cardiology, 2022
AIMS A unique Andean population lives in the highest city of the world (La Rinconada, 5,100 m, Peru) and frequently develops a maladaptive syndrome, termed chronic mountain sickness (CMS).
S. Doutreleau +11 more
semanticscholar +1 more source
AIMS A unique Andean population lives in the highest city of the world (La Rinconada, 5,100 m, Peru) and frequently develops a maladaptive syndrome, termed chronic mountain sickness (CMS).
S. Doutreleau +11 more
semanticscholar +1 more source
High Altitude Medicine & Biology, 2021
Richalet, Jean-Paul, Chantal Julia, and François J. Lhuissier. Evaluation of the Lake Louise Score for acute mountain sickness and its 2018 version in a cohort of 484 trekkers at high altitude. High Alt Med Biol. 22:353–361, 2021.
J. Richalet +2 more
semanticscholar +1 more source
Richalet, Jean-Paul, Chantal Julia, and François J. Lhuissier. Evaluation of the Lake Louise Score for acute mountain sickness and its 2018 version in a cohort of 484 trekkers at high altitude. High Alt Med Biol. 22:353–361, 2021.
J. Richalet +2 more
semanticscholar +1 more source
Altitude Sickness Prevention with Ibuprofen Relative to Acetazolamide.
American Journal of Medicine, 2019BACKGROUND Acute mountain sickness is a common occurrence for travel to high altitudes. Although previous studies of ibuprofen have shown efficacy for the prevention of acute mountain sickness, recommendations have been limited, as ibuprofen has not been
P. Burns +7 more
semanticscholar +1 more source
Altitude, Acute Mountain Sickness, and Acetazolamide: Recommendations for Rapid Ascent
High Altitude Medicine & Biology, 2020Toussaint, Claudia M., Robert W. Kenefick, Frank A. Petrassi, Stephen R. Muza, and Nisha Charkoudian. Altitude, acute mountain sickness, and acetazolamide: recommendations for rapid ascent. High Alt Med Biol. 22:5–13, 2021.
Claudia M Toussaint +4 more
semanticscholar +1 more source
Clinical evidence, 2005
Up to half of people who ascend to heights above 2500 m may develop acute mountain sickness, pulmonary oedema, or cerebral oedema, with the risk being greater at higher altitudes, and with faster rates of ascent.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent, and ...
Marc Moritz, Berger, Peter, Bärtsch
+9 more sources
Up to half of people who ascend to heights above 2500 m may develop acute mountain sickness, pulmonary oedema, or cerebral oedema, with the risk being greater at higher altitudes, and with faster rates of ascent.We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent, and ...
Marc Moritz, Berger, Peter, Bärtsch
+9 more sources
High Altitude Medicine & Biology, 2019
Background: Acute mountain sickness (AMS) is a common disease that may have a pulmonary component, as suggested by interstitial pulmonary edema quantified by the B-line score (BLS) on ultrasound (US).
C. Alsup +14 more
semanticscholar +1 more source
Background: Acute mountain sickness (AMS) is a common disease that may have a pulmonary component, as suggested by interstitial pulmonary edema quantified by the B-line score (BLS) on ultrasound (US).
C. Alsup +14 more
semanticscholar +1 more source

